AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$CAMP

Tardiff Daniel sold $8K of CAMP

Tardiff Daniel (Chief Scientific Officer) sold 1,738 shares of Camp4 Therapeutics Corp (CAMP) at $4.76 on 2026-08-19.

Original reporting
SEC EDGAR · Tardiff Daniel
Published Aug 20, 2026, 12:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CAMP
Neutral
high confidence
Mentioned
$CAMP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAMPNeutralLow
01

Why it matters

The disclosed sale is small and unlikely to move the stock.

02

Market read

Minor insider sell with limited trading relevance.

03

What to watch

No other material news accompanies the filing.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-19

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$CAMPNeutralHigh confidence
Context

Chief Scientific Officer sold 1,738 shares for $8,273 in a Form 4 filing on 2026-08-19.

Expected impact

Likely negligible price movement.

Evidence & confidence

The sale amount is small relative to market cap and does not signal a change in insider confidence.

Market effects

Sector

None; insider sale does not affect biotech sector broadly.

Regional

None; limited to the company.

Global

None

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Company
    Camp4 Therapeutics Corp

    Biotech firm listed on Nasdaq under ticker CAMP.

  • Insider
    Tardiff Daniel

    Chief Scientific Officer of Camp4 Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CAMP insider trading history →

Related articles

SEP 10
$CAMPMedAI 8/10

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

CAMP4 Therapeutics (Nasdaq: CAMP) received UK authorization to include sites in its Phase 1/2 trial for CMP-002, a potential treatment for SYNGAP1-related disorder. The company plans to start the trial in 4Q 2026, following clearances in Australia and Argentina. CMP-002 aims to restore SYNGAP protein levels, with no approved therapies currently available for this rare disorder.

finanznachrichten.de2 min
AUG 17
$CAMPMedAI 8/10

CAMP4 Q2 Net Loss Widens; On Track To Advance CMP-002 Into Phase 1/2 Trial In Q4 2026

CAMP4 Therapeutics (CAMP) reported Q2 2026 net loss of $33.5M, or $0.58/share, versus $12.6M, or $0.62/share, a year earlier. The wider loss was mainly due to a $20.9M non-cash derivative fair value change. R&D rose to $10.8M. CAMP4 received Australia and Argentina clearance for a Phase 1/2 CMP-002 trial, expected to start in Q4 2026, and raised $50.1M, extending runway to end-2028.

rttnews.com4 min
AUG 13
$CAMPMed

Camp4 Therapeutics Corp (CAMP): Results of Operations and Financial Condition

Camp4 Therapeutics Corp (CAMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth qua

SEC EDGAR 8-K4 min